Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Drug Utilization Review: Our Patients Deserve Our Very Best

Author(s):  Jackson Kathleen

Issue:  Nov/Dec 2023 - Volume 27, Number 6
View All Articles in Issue

Page(s):  450-453

Drug Utilization Review: Our Patients Deserve Our Very Best Page 1
Drug Utilization Review: Our Patients Deserve Our Very Best Page 2
Drug Utilization Review: Our Patients Deserve Our Very Best Page 3
Drug Utilization Review: Our Patients Deserve Our Very Best Page 4

Download in electronic PDF format for $75

Abstract:  In 1990, the Omnibus Budget Reconciliation Act included requirements for Medicaid patients in an effort to save the federal government money. The requirements included a prospective drug utilization review, patient counseling, and maintenance of patient records. Subsequently, in 1993, when the pharmacy practice requirements went into effect, this federal regulation became the standard of care for pharmacists and part of their professional duty. This article suggests that the pharmacy should review all active pharmaceutical ingredients and excipients that are dispensed at the pharmacy and list all interactions or potential side effects in the review, so that a proper drug utilization review can be performed.

Related Keywords: Kathleen Jackson, RPh, PhD (H.C.), FACP, U.S. Omnibus Budget Reconciliation Act, OBRA 90, medicaid, prospective drug utilization review, patient counseling, patient records, drug interactions, side effects, adverse effects, overdose potential

Related Categories: LEGAL, QUALITY CONTROL, ADVERSE DRUG EVENTS, PATIENT ASSESSMENT, PROFESSIONAL ISSUES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Drug Utilization Review: Our Patients Deserve Our Very Best
Jackson Kathleen
Nov/Dec 2023
Pg. 450-453

Drug Shortages & Discontinued Drugs: The Effects on Patients and Healthcare Providers
Allen Loyd V Jr
, Williams LaVonn A
Jul/Aug 2012
Pg. 294-298

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Compounded Medications in a Hospital Setting: Patient Counseling and Staff Education
McElhiney Linda F
May/Jun 2009
Pg. 224-229

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

Bedside Manner: Not Just for Doctors Anymore
Cormier Mindy
Mar/Apr 2015
Pg. 115-118

Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
Jan/Feb 2020
Pg. 30-36

Standing Together Fixing the Drug Quality and Security Act
Miller David G
Mar/Apr 2015
Pg. 104-106

Microwave Freeze-thaw Technique for Injectable Drugs: A Review Updated from 1980 to 2021
Hecq Jean-Daniel
, Soumoy Laura, Closset Mélanie, Colsoul Marie-Lise, Jamart Jacques, Galanti Laurence
Nov/Dec 2021
Pg. 446-462

Basics: Considerations and Background Information for Counseling Patients Using Compounded Suppositories
Allen Loyd V Jr
Jan/Feb 2022
Pg. 34-38

Compounding for the Pediatric Patient
Allen Loyd V Jr
Mar/Apr 1997
Pg. 84-86

Patient Satisfaction with Pharmacist Intervention and Consultation in HRT
DiMaggio Jennifer Lyn
, Reed-Kane Dana
Jul/Aug 2003
Pg. 258-263

Single-Patient Trials, Extemporaneously Compounded Products and Pharmaceutical Care
Fassett William E
Nov/Dec 2003
Pg. 441-447

Recommendations for Overcoming Barriers to Medication Therapy Management Implementation, Part 1: Review of Literature
Fyke Jeremy P
, Yale Robert N, Corbett Corinne, Litera Natalie
Jul/Aug 2008
Pg. 329-333

Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 2
Allen Loyd V
Jul/Aug 2015
Pg. 280-287

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Allen Loyd V Jr
Sep/Oct 2015
Pg. 389-390

Does Your Drug Expertise Include Clinical Pharmaceutics?
Newton David W
May/Jun 2016
Pg. 202-206

Patient-centered Care as Value-added Service by Compounding Pharmacists
McPherson Timothy B
, Fontane Patrick E, Day Jonathan R
Jul/Aug 2013
Pg. 339-343

Return to Top